Research & Development In Brief
This article was originally published in The Tan Sheet
Executive Summary
NSAIDs unsafe for heart attack patients
You may also be interested in...
Acetaminophen Under Scrutiny In California For Prop 65 Requirements
California extends deadline for data from cancer bioassays, epidemiological studies and genotoxicity tests for review of acetaminophen as a Prop 65 chemical due to carcinogenic potential. Deadline extended to May 29 in response to Consumer Healthcare Products Association request.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.